ArticleEuropean journal of medical research2025
Effectiveness and safety of orelabrutinib combined with rituximab, temozolomide, methotrexate, and cytarabine in intensive chemotherapy-unfit patients with PCNSL in China.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPrimary central nervous system lymphoma (PCNSL) is a rare and aggressive lymphoma subtype. Orelabrutinib (O), a novel and potent second-generation Bruton tyrosine kinase inhibitor, has shown impressive efficacy in PCNSL. This study aimed to evaluate the effectiveness and safety of the O-based regimen in the treatment of intensive chemotherapy-unfit patients with newly diagnosed PCNSL.
methodsIn this single-center, retrospective case series, we consecutively included 10 patients with PCNSL who were unfit for intensive chemotherapy, defined as an Eastern Cooperative Oncology Group performance status score of ≥ 3, a Karnofsky Performance Status score of ≤ 70, or a Sequential Organ Failure Assessment score of ≥ 2. All patients received the O-based regimen, including the combination of O, rituximab (R), and temozolomide (T; ORT), with or without methotrexate (M) or cytarabine (A; ORT-M/A), followed by ORT maintenance. The effectiveness outcomes were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).
resultsFollowing ORT-M/A treatment, six patients achieved a complete response (60.0% [95% CI 26.2-87.8]) and four achieved a partial response, yielding an ORR of 100.0% (95% CI 69.2-100.0). As of the data cutoff (September 7, 2025), the median follow-up of 23.7 months (range, 9.2-40.2). The corresponding 24-month PFS rate and 36-month OS rate were 80.0% (95% CI 51.6-100.0) and 90.0% (95% CI 73.2-100.0), respectively. The most common grade 3-4 treatment-related adverse events (AEs) were thrombocytopenia (100.0%) and leukopenia (90.0%). No serious AEs or treatment-related deaths were observed.
conclusionThe ORT-M/A chemotherapy regimen was efficacious and well-tolerated in our patients with PCNSL. This retrospective study provided a potential therapeutic strategy for PCNSL patients who are unfit for intensive chemotherapy and warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.